Current Report Filing (8-k)
21 April 2020 - 6:31AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): April 20, 2020 (April 16, 2020)
KRAIG
BIOCRAFT LABORATORIES, INC.
(Exact
name of registrant as specified in its charter)
Wyoming
|
|
333-146316
|
|
83-0458707
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
2723
South State St. Suite 150
Ann
Arbor, Michigan 48104
(Address of principal executive offices, including Zip Code)
(734)
619-8066
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
None
|
|
-
|
|
-
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
8.01 Other Events.
On
April 16, 2020, Kraig Biocraft Laboratories, Inc. (the “Company”) held a press conference to announce the development
of the first Knock In Knock Out transgenics in the Company’s history. The new technology, which is the result of over
ten years of effort, hits the target of one of the Company’s primary technological goals and opens the door for large scale
US production. The Company provided a recap of that announcement in a press release that was issued that same day.
A
copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item
9.01 Financial Statements and Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
April 20, 2020
|
KRAIG
BIOCRAFT LABORATORIES, INC.
|
|
|
|
|
By:
|
/s/
Kim Thompson
|
|
|
Kim
Thompson
|
|
|
Chief
Executive Officer,
Chief Financial Officer and Director
|
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From Apr 2024 to May 2024
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From May 2023 to May 2024